Table 5_Is full adherence mandatory? Real-world outcomes of completing perioperative chemo

A 14.7 KB document analyzes 164 patients with resectable non-small cell lung cancer to compare outcomes between those who completed a full perioperative chemoimmunotherapy regimen and those who did not. Authored by Zhoujunyi Tian and shared on figshare in May 2026, the study found no significant survival benefit from protocol completion but noted a higher incidence of any-grade adverse events. The analysis used Inverse Probability of Treatment Weighting to adjust for baseline characteristics.

Use Cases

• Compare recurrence-free and overall survival rates based on treatment completion status.
• Assess the relationship between adverse event incidence and full treatment regimen adherence.
• Identify patient subgroups (e.g., age <65, ECOG score 0) where treatment completion may confer a recurrence benefit.
• Analyze the predictive power of pathological nodal status for cancer recurrence.

Strengths

• Includes data on 164 patients divided into completed (n=37) and non-completed (n=127) groups.
• Reports specific statistical results, including hazard ratios (adjusted HR 1.14) and p-values for survival comparisons.
• Uses a real-world study design with adjusted baseline characteristics via Inverse Probability of Treatment Weighting.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 14.7 KB, indicating limited scope.

Provenance

Source

Zhoujunyi Tian via figshare

Collection Method

Retrospective analysis of patients with resectable non-small cell lung cancer who received neoadjuvant chemoimmunotherapy followed by surgery.

Freshness

Last updated 2026-05-28 04:45:39; freshness should be verified.